Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Robert E. Litman"'
Autor:
Christoph U. Correll, Robert E. Litman, Yuriy Filts, Jordi Llaudó, Dieter Naber, Ferran Torres, Javier Martínez
Publikováno v:
npj Schizophrenia, Vol 6, Iss 1, Pp 1-9 (2020)
Abstract To evaluate the efficacy and safety of Risperidone ISM® against placebo in patients with acute exacerbation of schizophrenia. A multicenter, randomized, double-blind, placebo-controlled study was conducted between June 2017 and December 201
Externí odkaz:
https://doaj.org/article/485f9847ecae4df6ad9a103f3ac27f37
Publikováno v:
Innov Clin Neurosci
INTRODUCTION: Recent research on the COVID-19 pandemic suggests that individuals who suffer from serious mental illness (SMI) are at heightened risk of infection and have increased mortality due to their illness and/or lack of access to healthcare. C
Autor:
Yuriy Filts, Robert E. Litman, Javier Martínez, Lourdes Anta, Dieter Naber, Christoph U. Correll
Publikováno v:
Schizophrenia Research. 246:258-259
Autor:
Javier Martínez, Lourdes Anta, Yuriy Filts, Christoph U. Correll, Robert E. Litman, Dieter Naber
Publikováno v:
Schizophrenia research. 239
Objective To evaluate long-term efficacy, safety and tolerability of Risperidone ISM® in patients with schizophrenia, a multicenter, open-label extension of the PRISMA-3 study was conducted. Methods Eligible placebo (unstable) and Risperidone ISM®
Autor:
Robert E. Litman, Kimberly E. Vanover, Dean F. Wong, Lorena Gapasin, Robert E. Davis, Michal Weingart, Yun Zhou, Weiguo Ye, Jelena Saillard, James Robert Brašić, Sharon Mates
Publikováno v:
Neuropsychopharmacology
Dopamine D2 receptor occupancy (D2RO) is a key feature of all currently approved antipsychotic medications. However, antipsychotic efficacy associated with high D2RO is often limited by side effects such as motor disturbances and hyperprolactinemia.
Autor:
Robert H. Yolken, Deepak Cyril D'Souza, Alexander J. Radnovich, Jenifer L. Vohs, Robert E. Litman, Diane Highum, Nicole F. Mehdiyoun, Sheldon H. Preskorn, Walter Dunn, Robert W. Buchanan, Matthew Macaluso, Ying Zhang, Rishi Kakar, Gerald A. Maguire, Emmalee Metzler, Andrew Visco, Ziyi Yang, Stephen R. Marder, Brent E. Wurfel, Evagelos Coskinas, Alan Breier, Debra Hoffmeyer, Keith H. Nuechterlein, Michael M. Francis, Faith Dickerson
Publikováno v:
Schizophrenia research. 206
Several studies have implicated herpes simplex virus-type 1 (HSV-1) in the pathophysiology of schizophrenia. A recent trial demonstrated that the anti-viral medication valacylovir, which prevents replication of activated HSV-1, improved selected cogn
Autor:
Kelly Papadakis, Robert E. Litman, György Németh, Suresh Durgam, Dayong Li, István Laszlovszky
Publikováno v:
International Clinical Psychopharmacology
This 6-week, double-blind, placebo-controlled, proof-of-concept study evaluated the efficacy, safety, and tolerability of low-dose (1.5-4.5 mg/day) and high-dose (6-12 mg/day) cariprazine in patients with acute exacerbation of schizophrenia (NCT00404
Autor:
Suresh Durgam, István Laszlovszky, György Németh, Willie Earley, Kaifeng Lu, Stephen Volk, Robert E. Litman
Publikováno v:
International Journal of Clinical Practice
Summary Introduction Global rating scale measures are useful for assessing the clinical relevance of patient change. Cariprazine, a dopamine D3 and D2 receptor partial agonist, is FDA‐approved for the adult treatment of acute manic/mixed episodes o
Autor:
Michelle Kramer, Robert E. Litman, Mariëlle Eerdekens, David Hough, Rosanne Lane, Yanning Liu, Pilar Lim
Publikováno v:
The International Journal of Neuropsychopharmacology. 13:635-647
We evaluated the efficacy and safety of the investigational long-acting injectable antipsychotic agent paliperidone palmitate (PP) in the treatment of schizophrenia. Patients were randomized to receive gluteal injections of placebo or PP (50 or 100 m
Autor:
Alan J. Cross, Stephen R. Zukin, Lev Gertsik, Mark A. Smith, Shane Raines, Robert E. Litman, James J. Doherty
Publikováno v:
Schizophrenia research. 172(1-3)
Introduction Activation of metabotropic glutamate (mGluR2/3) receptors has been proposed as an alternative mechanism to dopaminergic-based antipsychotics to correct glutamatergic deficits hypothesized to underlie schizophrenia symptoms. This study in